Discontinued ProductUnfortunately Ivachtin (Cat. No. 2636) has been withdrawn from sale for commercial reasons.
Potent, reversible inhibitor of caspase-3 (IC50 = 23 nM) that displays moderate selectivity over other caspases. Exhibits antiapoptotic activity in human Jurkat T cells treated with staurosporine; exhibits a higher level of protection than Z-VAD-FMK (Cat. No. 2163).
Sold with the permission of ChemDiv, Inc.
|Storage||Desiccate at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Preparing Stock Solutions
The following data is based on the product molecular weight 447.46. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.23 mL||11.17 mL||22.35 mL|
|5 mM||0.45 mL||2.23 mL||4.47 mL|
|10 mM||0.22 mL||1.12 mL||2.23 mL|
|50 mM||0.04 mL||0.22 mL||0.45 mL|
The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.
References are publications that support the products' biological activity.
Kravchenko et al (2005) Synthesis and structure-activity relationship of 4-substituted 2-(2-acetyloxyethyl)-8-(morpholine-4-sulfonyl)pyrrolo[3,4-c]quinoline-1,3-diones as potent caspase-3 inhibitors. J.Med.Chem. 48 3680 PMID: 15916416
View Related Products by Product Action
Keywords: Potent caspase-3 inhibitors inhibits Caspases Proteinases Proteases Caspases
Citations for Ivachtin
Citations are publications that use Tocris products.
Currently there are no citations for Ivachtin.
Literature in this Area
Cell Cycle & DNA Damage Repair Poster
In normal cells, each stage of the cell cycle is tightly regulated, however in cancer cells many genes and proteins that are involved in the regulation of the cell cycle are mutated or over expressed. Adapted from the 2015 Cancer Product Guide, Edition 3, this poster summarizes the stages of the cell cycle and DNA repair. It also highlights strategies for enhancing replicative stress in cancer cells to force mitotic catastrophe and cell death.
Huntington's Disease Poster
Huntington's disease (HD) is a monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the MSN intracellular signaling pathways implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.
Programmed Cell Death Poster
There are two currently recognized forms of programmed cell death: apoptosis and necroptosis. This poster summarizes the signaling pathways involved in apoptosis, necroptosis and cell survival following death receptor activation, and highlights the influence of the molecular switch, cFLIP, on cell fate.